8-K: Inspire Medical Systems Reports Strong Q4, FY25 Revenue; Appoints New CFO

Inspire Medical Systems announced preliminary strong Q4 and full-year 2025 revenue results, provided initial 2026 guidance, and appointed Matt Osberg as its new Executive Vice President and Chief Financial Officer.

Summary

• Preliminary unaudited revenue for the fourth quarter of 2025 is anticipated to be in the range of $268.9 million to $269.1 million, an approximately 12% increase over the same quarter of 2024.
• Preliminary unaudited revenue for full year 2025 is anticipated to be in the range of $911.8 million to $912.0 million, an approximately 14% increase over full year 2024.
• Initial full year 2026 revenue guidance is anticipated to be in the range of $1,003 million to $1,013 million, representing a 10% to 11% increase over full year 2025.
• Matt Osberg has been appointed as Executive Vice President and Chief Financial Officer, effective January 19, 2026.
• The company successfully launched the Inspire V neurostimulation system in 2025, with significant momentum and strong acceptance throughout the second half of the year.
• Recent reimbursement developments are viewed as a positive step, but the 2026 outlook does not currently include any contribution from increased reimbursement.
• Richard J. Buchholz transitioned to interim Chief Financial Officer through the filing of the company's 2025 10-K.

Sentiment

Score: 8

Explanation: The filing presents strong preliminary financial results for Q4 and full-year 2025, coupled with positive 2026 revenue guidance. The successful launch of the Inspire V system, compelling clinical data, and the appointment of an experienced CFO are significant positives. While the results are unaudited and the guidance excludes potential reimbursement benefits, these are standard cautionary statements. The overall outlook is highly positive, indicating strong momentum and strategic execution.

Positives

• Strong preliminary Q4 2025 revenue growth of approximately 12% year-over-year, reaching $268.9 million to $269.1 million.
• Robust preliminary Full Year 2025 revenue growth of approximately 14% year-over-year, anticipated to be $911.8 million to $912.0 million.
• Positive initial Full Year 2026 revenue guidance projecting 10% to 11% growth, aiming for over $1 billion in revenue ($1,003 million to $1,013 million).
• Successful launch and strong acceptance of the Inspire V neurostimulation system in the U.S., with 100% of physicians trained and over 95% of contracts signed.
• Positive safety and efficacy data presented for Inspire V from the Singapore clinical study, showing 100% successful implants, 20% reduction in surgical time, and a 79.5% response rate.
• Appointment of Matt Osberg as CFO, an accomplished C-suite financial executive with over 20 years of global financial leadership experience.
• Recent reimbursement developments are viewed as a positive step, indicating potential future upside not yet included in guidance.
• Consistent and continuous improvement in device reliability, with global system survivability to revision and explant showing positive trends year after year.
• Three independent studies demonstrate Inspire therapy reduces the long-term cardiovascular burden of disease more than CPAP, including lower risk for stroke, heart-failure exacerbations, revascularization, and all-cause mortality.
• High patient satisfaction rates: 91% say Inspire is better than CPAP, 93% would recommend it, and 90% are satisfied or very satisfied with Inspire therapy.

Negatives

• Preliminary financial results are unaudited and subject to change upon completion of all quarter and year-end close processes and the annual audit.
• The initial 2026 revenue guidance does not include any contribution from increased reimbursement at this time, indicating a conservative outlook or ongoing uncertainty in this area.
• The company has a history of operating losses and dependency on its Inspire therapy for revenues, as noted in the risk factors.

Risks

• Financial results may fluctuate significantly and may not fully reflect the underlying performance of the business.
• History of operating losses and dependency on Inspire therapy for revenues.
• Commercial success and market acceptance of Inspire therapy.
• Ability to achieve and maintain adequate and clear levels of coverage or reimbursement for Inspire therapy or any future products.
• Competitive companies, technologies, and pharmaceuticals in the industry.
• Involvement in current or future legal disputes or regulatory proceedings.
• Ability to expand indications and develop and commercialize additional products and enhancements to Inspire therapy.
• Future results of operations, financial position, research and development costs, capital requirements, and needs for additional financing.
• Ability to accurately forecast customer demand for Inspire therapy and manage inventory.
• Dependence on third-party suppliers, vendors, and contract manufacturers.
• Consolidation in the healthcare industry.
• Ability to expand, manage, and maintain the direct sales and marketing organization, and to market and sell Inspire therapy in markets outside of the U.S.
• Ability to manage growth.
• Ability to hire and retain senior management and other highly qualified personnel.
• Risk related to product liability claims and warranty claims.
• Ability to address quality issues that may arise with Inspire therapy.
• Ability to successfully integrate any acquired business, products, or technologies.
• Changes in global macroeconomic trends.
• Business model and strategic plans for products, technologies, and business, including implementation thereof.
• The impact of glucagon-like peptide 1 (GLP-1) class of drugs on demand for Inspire therapy.
• Risks related to information technology and cybersecurity.
• Ability to commercialize or obtain regulatory approvals for Inspire therapy, or the effect of delays in commercializing or obtaining regulatory approvals.
• FDA or other U.S. or foreign regulatory actions affecting the company or the healthcare industry generally.

Future Outlook

The company anticipates full year 2026 revenue to be between $1,003 million and $1,013 million, representing a 10% to 11% increase over 2025. This outlook does not currently factor in any potential contributions from increased reimbursement rates, which the company is actively seeking clarification on. The company expects continued adoption of Inspire therapy globally, further innovation, and continued growth driven by its strategic initiatives.

Management Comments

• "We are very pleased with our strong preliminary revenue performance in the fourth quarter as the team executed exceptionally well and finished the year with significant momentum." Tim Herbert, Chairman and Chief Executive Officer.
• "2025 was a transition year for the company with the launch of the Inspire V system, and momentum grew significantly throughout the second half of the year, and we are very proud of the strong acceptance of this fifth-generation Inspire system further evidenced by the safety and clinical evidence that was presented throughout the year." Tim Herbert, Chairman and Chief Executive Officer.
• "With the momentum we are seeing, we are pleased to reaffirm the preliminary outlook we provided on our third quarter earnings call of 10% to 11% revenue growth in 2026 as compared to 2025." Tim Herbert, Chairman and Chief Executive Officer.
• "We view the recent reimbursement developments as a positive step and are continuing to work with the relevant agencies to gain clarification on coding. Our outlook does not include any contribution from increased reimbursement at this time, and we will continue to provide updates, including on our upcoming earnings call." Tim Herbert, Chairman and Chief Executive Officer.
• "We are very excited to have Matt Osberg join Inspire and bring his years of public company experience to take us through our next wave of growth as we continue the adoption of Inspire therapy globally." Tim Herbert, Chairman and Chief Executive Officer.
• "Finally, we wish to thank Rick Buchholz for his many years at Inspire and wish him well in his future endeavors." Tim Herbert, Chairman and Chief Executive Officer.

Industry Context

Inspire Medical Systems operates in the medical technology sector, specifically targeting obstructive sleep apnea (OSA) with its innovative neurostimulation therapy. The market for OSA treatment is substantial and largely underpenetrated, with an estimated 23 million adults suffering from moderate to severe OSA and approximately 500,000 being eligible for Inspire therapy. The company's strong growth, successful launch of the Inspire V system, and development of the SleepSync digital health platform position it favorably against traditional treatments like CPAP, which suffer from low patient compliance (35-65%). The compelling clinical data, particularly regarding Inspire's superior cardiovascular outcomes compared to CPAP, reinforces its competitive advantage. The company acknowledges the potential impact of GLP-1 class drugs on OSA demand as a future risk, demonstrating awareness of broader pharmaceutical trends that could influence its market.

Comparison to Industry Standards

• Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology of its kind for moderate to severe obstructive sleep apnea, establishing a first-mover advantage.
• Inspire therapy demonstrates significantly higher patient adherence compared to CPAP, with patients averaging 5.7 hours of nightly use at 12 months, contrasting with typical CPAP compliance rates of 35-65%.
• Three independent studies (Virginia Commonwealth University, Thomas Jefferson University, University of Texas Medical Branch) using large claims databases (e.g., TriNetX) indicate that Inspire therapy reduces the risk of adverse cardiovascular events, including stroke, heart-failure exacerbations, revascularization, and all-cause mortality, more effectively than CPAP.
• Inspire patients report high satisfaction (90% satisfied or very satisfied) and willingness to recommend (93%), which is a strong indicator of patient experience compared to the known discomforts and challenges associated with CPAP.
• The Inspire V system has shown a 20% reduction in surgical time, improving procedural efficiency compared to previous generations and potentially other surgical alternatives for OSA like Uvulopalatopharyngoplasty (UPPP) or Maxillomandibular Advancement (MMA), which have variable success rates (30-60%) and longer recovery periods.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders**: Positive impact due to strong preliminary financial results, optimistic future guidance, and the appointment of an experienced CFO, which could lead to increased investor confidence and potential share price appreciation.
• **Employees**: Positive impact from a growing and stable company, with continued investment in innovation and a strengthened leadership team, potentially fostering a positive work environment and career opportunities.
• **Customers (Patients)**: Positive impact through continued access to innovative and effective Inspire therapy, enhanced by the successful launch of the Inspire V system and the SleepSync digital health platform, leading to improved patient outcomes and quality of life.
• **Suppliers/Vendors**: Potential for increased business volume and stable partnerships due to the company's strong growth trajectory and demand for its products.
• **Creditors**: Enhanced financial stability and growth prospects improve the company's creditworthiness and ability to meet its financial obligations.

Next Steps

• Complete all quarter and year-end close processes for the full consolidated financial statements for the period ended December 31, 2025.
• Undergo the annual audit of the financial statements for the fiscal year ended December 31, 2025, by the independent registered public accounting firm.
• Provide further updates, including on reimbursement developments, during the upcoming earnings call.
• Continue to work with relevant agencies to gain clarification on coding for reimbursement.
• Continue the adoption of Inspire therapy globally.
• Further develop additional utility tools for the SleepSync digital health platform.
• Invest in research and development to drive breakthrough technology innovation and expanded indications.
• Facilitate international market expansion by further penetrating existing markets and entering into new geographical locations.

Key Dates

Recommendation

The filing presents exceptionally strong preliminary financial results for Q4 and full-year 2025, significantly exceeding expectations with double-digit revenue growth. The initial 2026 guidance projects continued robust growth, surpassing the $1 billion revenue mark. The successful launch and strong market acceptance of the innovative Inspire V system, coupled with compelling clinical data demonstrating superior patient outcomes and cardiovascular benefits over CPAP, reinforce the company's competitive advantage. The appointment of a highly experienced CFO further strengthens the management team. Despite the preliminary nature of the results and conservative guidance regarding reimbursement, the overall trajectory, large underpenetrated market opportunity, and strong operational execution position Inspire Medical Systems for substantial future growth, making it a compelling 'strong buy' for long-term investors.

Keywords

Obstructive Sleep Apnea, OSA, Inspire Medical Systems, INSP, neurostimulation, medical technology, sleep apnea treatment, Inspire V, financial results, revenue guidance, CFO appointment, healthcare, medical device, sleep therapy, hypoglossal nerve stimulation, SleepSync